Dr. Reddy's Laboratories Ltd. closed 18.89% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Dr. Reddy's Laboratories Ltd. closed 17.55% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.

Allspring Global Investments Holdings LLC grew its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by ...

Welcome to the Dr Reddys Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a ...

Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...

Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a daratumumab biosimilar candidate to Johnson & Johnson’s (J&J) Darzalex & ...

View Our Latest Report on Dr. Reddy’s Laboratories Dr. Reddy’s Laboratories Trading Down 0.3 % NYSE RDY opened at $13.57 on Wednesday. The company has a current ratio of 1.92, a quick ratio of ...

31 May, 2006 28 Aug, 2006 1:1 For every 1 share held; Holder will receive 1 bonus shares. 24 Mar, 1994 08 Apr, 1994 2:1 For every 1 share held; Holder will receive 2 bonus shares. 30 Sep, 1992 04 ...

An analyst from YES Securities said that Vedanta has faced downward pressure, leading to a gradual decline in its stock price ...

Indian drugmakers earn a significant share of revenue from the US, the largest importer of Indian pharma products ...